CANF
$0.99
Can-Fite Biopharma Ltd ADR
$.01
1.01%
CANF
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.14)
Revenue:  N/A
Friday
Feb 25
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CANF reports earnings?
Beat
Meet
Miss

Where is CANF's stock price going from here?
Up
Flat
Down
Stock chart of CANF
Analysts
Summary of analysts' recommendations for CANF
Score
Grade
Pivots
Resistance
$1.09
$1.07
$1.02

$1.00

Support
$0.95
$0.93
$0.88
Tweet
Growth
Description
Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel.